OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 02, 2016 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016, at 1:20 p.m. GMT (8:20 a.m. ET).
A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the TSPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the Company’s third product line focused on the transplantation market. In addition to these three product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
[email protected]
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
[email protected]
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
[email protected]


EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Robinhood Expands Sports Event Contracts With Player Performance Wagers 



